NEWS Life Molecular Imaging Announces Collaboration to Provide Both its Amyloid and Tau PET Imaging Agents for Research of Alzheimer’s Disease in a Large Consortium Clinical Trial Sponsored by National Institute on Aging 23 July 2024 LEARN MORE
NEWS Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Mobile, AL 9 July 2024 LEARN MORE
NEWS Life Molecular Imaging Enters Agreement With Lantheus to Sub-License its Radiotheranostic Agent RM2 Targeting GRPR in Prostate and Breast Cancers 27 June 2024 LEARN MORE
NEWS Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland 4 April 2024 LEARN MORE
NEWS Life Molecular Imaging and Oryx Isotopes Industrial Company announce a Strategic Partnership for the Production and Distribution of Florbetaben (18F) in the Kingdom of Saudi Arabia and other countries in reach 6 February 2024 LEARN MORE
NEWS Life Molecular Imaging and SOFIE announce Neuraceq® availability in Houston 9 January 2024 LEARN MORE
NEWS CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan 22 November 2023 LEARN MORE
NEWS Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China 13 October 2023 LEARN MORE
NEWS Life Molecular Imaging announces presentation of new scientific data at the European Association of Nuclear Medicine annual meeting 2023 5 September 2023 LEARN MORE
